Alivegen’s ALG-801 named FDA orphan drug for PAH
The FDA granted orphan drug designation to ALG-801, Alivegen’s next-generation treatment candidate for pulmonary arterial hypertension (PAH).
0 Comments
Alivegen’s ALG-801 named FDA orphan drug for PAH
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed